Ocular Hypertension Market Expected to Experience Major Growth by 2034, According to DelveInsight

The Ocular Hypertension market size was valued ~2,954 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

NEVADA, LA, UNITED STATES, June 25, 2024 /EINPresswire.com/ --
DelveInsight’s “Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the Ocular Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ocular Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ocular Hypertension Market Forecast

Some of the key facts of the Ocular Hypertension Market Report:
The Ocular Hypertension market size was valued ~2,954 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2022, the United States had the highest market size for Ocular Hypertension (OHT), totaling USD 1,628 million. In contrast, the combined market size of EU4 and the UK was USD 887 million, and Japan recorded USD 438 million.
Among the countries in EU4 and the UK, Germany recorded the highest market size for Ocular Hypertension (OHT) with USD 231 million in 2022. In contrast, Spain reported the lowest market size, totaling USD 153 million during the same period.
According to Delveinsight’s analysis, in 2022, the total number of existing cases of Ocular Hypertension across the 7MM was estimated at about 21,104,768. The United States had the highest number of cases among these countries in 2022, and these numbers are expected to rise further by 2034.
In EU4 and the UK combined, there were around 8,258,082 cases of Ocular Hypertension in 2022. Germany showed the highest prevalence among these countries, with about 2,154,448 cases, while Spain had the lowest prevalence with 1,428,018 cases in the same year.
According to DelveInsight’s analysis, Japan had around 3,879,588 cases of Ocular Hypertension in 2022, marking it as the country with the second highest prevalence after the US within the 7MM.
Among the diagnosed prevalent cases specific to gender, females outnumbered males. In 2022, within the EU4 and the UK, Germany reported 928,641 cases among males and 1,225,807 cases among females, the highest among all countries in this region. Conversely, Spain had the lowest numbers, with 615,525 cases among males and 812,493 cases among females.
Emerging therapies for Ocular Hypertension (OHT) such as PDP-716 by Visiox Pharma, Sepetaprost (DE-126/ONO-9054) by Santen/Ono Pharmaceutical, NCX 470 by Nicox Ophthalmics, LL-BMT1 by MediPrint Ophthalmics, and others show promising potential. These treatments are anticipated to significantly impact the Ocular Hypertension market landscape in the coming years.
Key Ocular Hypertension Companies: Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others
Key Ocular Hypertension Therapies: NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others
The Ocular Hypertension epidemiology based on gender analyzed that females are more affected than males
The Ocular Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ocular Hypertension pipeline products will significantly revolutionize the Ocular Hypertension market dynamics.

Ocular Hypertension Overview
Ocular hypertension refers to the condition where the pressure inside the eye, known as intraocular pressure (IOP), is higher than normal. This increased pressure can lead to potential damage to the optic nerve, which is crucial for vision. It's important to note that ocular hypertension doesn't always result in glaucoma, but it is considered a significant risk factor for the development of the condition.

Get a Free sample for the Ocular Hypertension Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Ocular Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ocular Hypertension Epidemiology Segmentation:
The Ocular Hypertension market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Ocular Hypertension
Prevalent Cases of Ocular Hypertension by severity
Gender-specific Prevalence of Ocular Hypertension
Diagnosed Cases of Episodic and Chronic Ocular Hypertension

Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ Ocular Hypertension Epidemiology Forecast

Ocular Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ocular Hypertension market or expected to get launched during the study period. The analysis covers Ocular Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ocular Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ocular Hypertension Therapies and Key Companies
NCX 470: Nicox Ophthalmics
Nyxol: Ocuphire Pharma
Sepetaprost(DE-126/ONO-9054/STN1012600 ): Santen Inc. /Ono Pharmaceutical
LL-BMT1: MediPrint Ophthalmics
PDP-716: Visiox Pharma/ Sun Pharma Advanced Research Company
JV-GL1: JeniVision, Inc.
NCX 470: Nicox Ophthalmics, Inc.
Kinezodianone R hydrochloride: Laboratoires Thea
G2-TR intraocular implant containing travoprost: Glaukos Corporation
H-1337: D. Western Therapeutics Institute, Inc.
AGN-193408 SR: AbbVie
Latanoprost ophthalmic solution: TearClear Corp
OTX-TIC: Ocular Therapeutix, Inc.
PER-001: Perfuse Therapeutics, Inc.

Scope of the Ocular Hypertension Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Ocular Hypertension Companies: Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others
Key Ocular Hypertension Therapies: NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others
Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Ocular Hypertension Unmet Needs, KOL’s views, Analyst’s views, Ocular Hypertension Market Access and Reimbursement

To know more about Ocular Hypertension companies working in the treatment market, visit @ Ocular Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents
1. Ocular Hypertension Market Report Introduction
2. Executive Summary for Ocular Hypertension
3. SWOT analysis of Ocular Hypertension
4. Ocular Hypertension Patient Share (%) Overview at a Glance
5. Ocular Hypertension Market Overview at a Glance
6. Ocular Hypertension Disease Background and Overview
7. Ocular Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Ocular Hypertension
9. Ocular Hypertension Current Treatment and Medical Practices
10. Ocular Hypertension Unmet Needs
11. Ocular Hypertension Emerging Therapies
12. Ocular Hypertension Market Outlook
13. Country-Wise Ocular Hypertension Market Analysis (2020–2034)
14. Ocular Hypertension Market Access and Reimbursement of Therapies
15. Ocular Hypertension Market Drivers
16. Ocular Hypertension Market Barriers
17. Ocular Hypertension Appendix
18. Ocular Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here